User:Mr. Ibrahem/Rucaparib

From Wikipedia, the free encyclopedia
Mr. Ibrahem/Rucaparib
Clinical data
Pronunciation/ruːˈkæpərɪb/ roo-KAP-ər-ib
Trade namesRubraca
Other namesAG014699
AHFS/Drugs.comMonograph
MedlinePlusa617002
License data
Pregnancy
category
  • Not recommended
Routes of
administration		By mouth (tablets)
Drug classPARP inhibitor[1]
Legal status
Legal status
  • UK: POM (Prescription only)[2]
  • US: ℞-only
  • EU: Rx-only
  • In general: ℞ (Prescription only)
Pharmacokinetic data
Bioavailability30–45% (Tmax = 1.9 hours)
Protein binding70% (in vitro)
MetabolismLiver (primarily CYP2D6; 1A2 and 3A4 to a lesser extent)
Elimination half-life17–19 hours[1]
Identifiers
  • 8-Fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one
Chemical and physical data
FormulaC19H18FN3O
Molar mass323.371 g·mol−1
3D model (JSmol)
  • CNCc1ccc(cc1)c2[nH]c3cc(F)cc4C(=O)NCCc2c34
  • InChI=1S/C19H18FN3O/c1-21-10-11-2-4-12(5-3-11)18-14-6-7-22-19(24)15-8-13(20)9-16(23-18)17(14)15/h2-5,8-9,21,23H,6-7,10H2,1H3,(H,22,24)
  • Key:HMABYWSNWIZPAG-UHFFFAOYSA-N

Rucaparib, sold under the brand name Rubraca, is a medication used for ovarian cancer, fallopian tube cancer, peritoneal cancer, and prostate cancer.[1][3] It is used after other treatments have failed.[4] It is taken by mouth.[1]

Common side effects include tiredness, nausea, kidney problems, liver problems, low red blood cells, abnormal taste, diarrhea, low platelets, and abdominal pain.[4] Other side effects may include acute myeloid leukemia and low neutrophils.[5] Use during pregnancy may harm the baby.[5] It is a PARP inhibitor, which block DNA repair in cells with mutation in the BRCA gene.[1]

Rucaparib was approved for medical use in the United States in 2016 and Europe in 2018.[5][4] In the United States it costs about 9,100 USD per month as of 2021.[6]

References[edit]

  1. ^ a b c d e f "DailyMed - RUBRACA- rucaparib tablet, film coated". dailymed.nlm.nih.gov. Archived from the original on 9 May 2020. Retrieved 19 October 2021.
  2. ^ "Rubraca 200mg film-coated tablets - Summary of Product Characteristics (SmPC)". (emc). 19 June 2019. Archived from the original on 29 August 2021. Retrieved 17 May 2020.
  3. ^ a b "Rucaparib Camsylate - National Cancer Institute". www.cancer.gov. 3 January 2017. Archived from the original on 9 July 2021. Retrieved 19 October 2021.
  4. ^ a b c d e "Rubraca". Archived from the original on 6 August 2020. Retrieved 19 October 2021.
  5. ^ a b c "Rucaparib Monograph for Professionals". Drugs.com. Archived from the original on 21 January 2021. Retrieved 19 October 2021.
  6. ^ "Rubraca Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 20 March 2021. Retrieved 19 October 2021.
Retrieved from "https://en.wikipedia.org/w/index.php?title=User:Mr._Ibrahem/Rucaparib&oldid=1217725378"